Chordate Medical Holding AB (publ) (“Chordate Medical” or the “Company“) announces that the directed set-off issue to underwriters who have chosen to receive guarantee compensation in the form of newly issued shares in the Company announced on January 18, 2023 (the “Compensation Issue“) has been registered with the Swedish Companies Registration Office (sw. “Bolagsverket”). Distribution of shares is expected to commence on January 25, 2023.
Financial and legal advisers
Västra Hamnen Corporate Finance AB acts as financial adviser and Wistrand Advokatbyrå acts as legal adviser to Chordate Medical in connection with the Compensation Issue.
The information was submitted, through the contact person above, for publication on January 24 at 19.20 2023 (CET).
N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.